Lederle R M
Medizinische Klinik I, Städtische Kliniken Dortmund, Akademisches Lehrkrankenhaus.
Fortschr Med. 1991 Oct 20;109(30):621-4.
An open multicenter trial involving 7,232 participating physicians, was performed to assess the anti-hypertensive efficacy and tolerance of a fixed combination of captopril and hydrochlorothiazide (Capozide) given once daily to 34,976 patients (mean age 58.5 +/- 11.4 years) with mild-to-moderate hypertension inadequately controlled by previous anti-hypertensive treatment. After 8 weeks, the response rate to a daily dose of Capozide 25 or 50 was 87.2%. Within this period, the mean systolic/diastolic blood pressure dropped from 175 +/- 16/103 +/- 5 mmHg to 150 +/- 13/88 +/- 7 mmHg (p less than 0.001). In 81% of the questionnaires, treatment with the combination was rated superior to the previous treatment; in only 5% was it considered inadequate. Side effects, for the most part mild, were reported by 7.4% of the patients. Treatment with Capozide was discontinued, or another form of treatment substituted in 12.9% of the cases.
一项开放性多中心试验纳入了7232名参与的医生，对34976例（平均年龄58.5±11.4岁）轻度至中度高血压患者进行研究，这些患者之前的抗高血压治疗未能充分控制血压，试验旨在评估每日一次给予卡托普利和氢氯噻嗪固定复方制剂（复方卡托普利片）的降压疗效和耐受性。8周后，每日服用25或50剂量复方卡托普利片的有效率为87.2%。在此期间，平均收缩压/舒张压从175±16/103±5 mmHg降至150±13/88±7 mmHg（p<0.001）。在81%的调查问卷中，该复方制剂治疗的评分高于之前的治疗；只有5%的问卷认为其治疗效果不佳。7.4%的患者报告了副作用，大部分副作用较轻。12.9%的病例停用了复方卡托普利片治疗或换用了其他治疗方式。
